HER2DX risk score was significantly associated with relapse-free interval in patients with clinically low-risk HER2+ breast cancer who took part in both trials.
Completed APT and ATEMPT studies were essential in establishing new anti-HER2-based treatment strategies for patients with early-stage HER2+ breast cancer.
